Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
9 Tips for Avoiding Tax Season Cyber Scams 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
AstraZeneca Plc got rid of its 7.7% stake in Moderna, and it was sold for more than $1 billion. The sale happened following the surge of the British–Swedish multinational pharmaceutical and biopharmaceutical company’s shares due to its COVID-19 vaccine breakthrough.
The stake selling move by the pharma firm
Then again, Reuters reported that it is not clear as to when AstraZeneca sold its Moderna stake. When contacted to clarify and provide more details about the matter, the outlet stated that both AstraZeneca and Moderna were not able to respond to the requests for comments immediately.
But despite the sale, it was said that AstraZeneca will still retain its team up with Moderna Inc. for the research and production of drugs for treating other diseases. The British–Swedish pharmaceutical company may also sell its AstraZeneca/Oxford University coronavirus vaccine on a commercial scale in the future if COVID-19 becomes endemic.
At any rate, the vaccine that Moderna made for COVID-19 has been approved by the Food and Drug Administration (FDA) for emergency use in the U.S. With its vaccine alone, the American pharmaceutical and biotechnology company says it is expecting $18.4 billion from the sale of its coronavirus vaccine this year.
How AstraZeneca will use the cash from the sale
The Times reported that AstraZeneca was Moderna’s second-biggest investor in 2020, but now it has sold its 7.7% stakes. The gains from the sale of Moderna holding is equivalent to $1.2 billion, and this will be added to Astra’s funds intended for developing its own drug line.
Part of the cash will also be used to complete AstraZeneca’s purchase of the American pharmaceutical that makes drugs for the treatment of rare diseases and disorders, Alexion. This was purchased by Astra for $39 billion, which makes it the company’s biggest acquisition.
AstraZeneca’s purchase of Alexion was announced in December 2020. It was announced that the rare disease unit would be based in Boston once the deal is completed. Finally, the procurement of the pharma firm will strengthen AstraZeneca’s income and will further help Alexion’s presence on the global stage to become more prominent.
